Список литературы (5000162560)
1. Tumor of the Breast and female genital organs. World Health Organization Classification of Tumours/edit. By FA Tavassoli, P Devilee. Lyon: IARC Press, 2003. 432 с.
2. Золотарева ЕН, Доросевич АЕ. Современные аспекты морфогенеза рака молочной железы. Арх. Пат. 2004; 1: 51–53.
3. Дисгормональные гиперплазии молочных желез/Под ред. ДИ Головина. Ленинград: Медицина, Ленинградское отделение, 1969. 111 с.
4. Білинський БТ, Шпарик ЯВ. Сучасні проблеми медикаментозної терапії раку грудної залози. Львів: Галицька видавнича спілка, 2001. 156 с.
5. Патолого-анатомическая діагностика опухолей человека. Руководство для врай /Под ред. НА Краевского, АС Смольянникова, ДС Саркисова. Москва: Медицина, 1993. 687 с.
6. Greenough RB. Varying degrees of malignancy in cancer of the breast. J Cancer Res. 1925; 9: 452–463.
7. Patey DH, Scarff RW. The position of histology in the prognosiso carcinoma of the breast. Lancet 1928: 1; 801–804.
8. Elston CW. Grading of invasive carcinoma of the breast. In: Page DL, Anderson TJ, eds. Disgnostic Histopathology of the Breast. Edinburgh: Churchill Livingstone. 1987; 300–311.
9. Elston CW, Ellis IO. Pathological prognostic factors in breast cancer. 1. The value of histological grade in breast cancer: experience from a large study with long-term follow-up. Histopathology 1991; 19: 403–410.
10. Simpson JF, Page DL. Status of breast cancer prognostication based on histopathologic data. Am J Clin. Pathol. 1994; 102 (Suppl 1): 53–58.
11. Pereira H, Pinder SE, Sibberin DM, Galea MH, Elston CW, Blamey RW, Robertson JR, Ellis IO. Pathological prognostic factors in breast carcinoma. IV: shouldyou be a typer or a grader? A comparative study of two histologic prognostic features in operable breast carcinoma. Histopathol 1995; 27: 219–226.
12. Bloom HJG. Prognosis in carcinoma of the breast. Br J Cancer 1950; 4: 259–288.
13. Bloom HJG. Further studies on prognosis of breast carcinoma. Br Cancer 1950; 4: 347–367.
14. Bloom HJG, Field JR. Impact of tumor grade and host resistance on survival of women and breast cancer. Cancer 1971; 28: 1580–1589.
15. Bloom HJG, Richardson WW. Histological grading and prognosis in breast cancer. Br J Cancer 1957; 11: 359–377.
16. Stenkvist B, Westman-Naeser S, Vegelius J, Holmquist J, Nordine B, Bengtysson E, Ericksson O. Analysis of reproducibility of subjective grading systems for breast carcinoma. J Clin Pathol 1979; 32: 979–985.
17. Frierson HF, Wolber RA, Berean KW, Franquemont DW, Gaffey MJ, Boyd JC, Wilbur DC. Interobserver reproducibility of the Nottingham modification of the Boom and Richardson histologic grading scheme for infiltrating ductal carcinoma. Am J Clin Pathol 1995; 103: 195–198.
18. Fiisher CW, Redmond C, Fisher B. Histologic grading of breast cancer. Path Annu 1980; 15: 239–251.
19. Doussal LE, Tubiana-Hulin M, Friedman S, Hacene K, Spyratos F, Brunet M. Prognostic value of histologic grade nuclear components of Scarff-Bloom-Richardson (SBR). An improved score modification based on multivariate analysis of 1262 invasive ductal breast carcinomas. Cancer 1989; 64: 1914–1921.
20. Benner SE, Clark GM, McGuire WL. Steroid receptors, cellular kinetics and lymph node status as prognostic factors in breast cancer. Am J Med Sci 1988; 296: 59–66.
21. Collan Y, Haapasalo H. The value of mitotic counting in the assessment of prognosis and proliferation in human tumors. J Pathol 1991; 163: 361–364.
22. Frierson HF (Ed).The need for improvement in flow cytometric analysis of ploidy and S-phase fractin. Am J Clin Pathol 1991; 95: 439–441.
23. Linden MD, Torres FX, Kubus J, Zarbo RJ. Clinical application of morphologic and immunocytochemical assessments of cell proliferation. Am J Clin Pathol 1992; 97: 4–13.
24. Weinberg DS. Proliferation indices in solid tumors. Adv Pathol Lab Med 1992; 5: 163–191.
25. Diest PJ, Baak JPA. The norphometric prognostic index is the strongest prognosticator in premenopausal lymph node-negative and lymph node-positive breast cancer patients. Hum Pathl 1991; 22: 326–330.
26. Jannink I, van Diest PJ, Baak JPA. Comparison of the prognostic value of four methods to assess mitotic activity in 186 invasive breast cancer patients: classical and random mitotic activity assessments with correction fo volume percentage of epithelium. Hum Pathol 1995; 26: 1086–1092.
27. Kreipe H, Alm P, Olsson H, Hauberg M, Fischer L, Parwaresch MR. Prognosticsignificance of a formalin-resistant nuclear proliferation antigen in mammary carcinomas as determined by the monoclonal antibody Ki-S1. Amer J Pathol 1993; 142(2): 651.
28. Bakshi RP, Galande S, Muniyappa K. Functional and regulatory characteristics of eukaryotic type II DNA topoisomerase (review). Crit Rev Biochem Mol Biol 2001; 36: 1–37.
29. Verhoeven D, Bourgeois N, Derde MP, Kaufman L, Buyssens N. Comparison of cell growth in different parts of breast cancers. Hitopathology 1990; 17: 505–9.
30. Упоров АВ, Цырлина АВ, Пожарисский КМ. Иммуногистохимическое изучение пролиферативной активности клеток рака молочной железы по экспрессии ядерного антигена пролиферирующих клеток (PCNA). Вопр. онкол. 1998; 44 (1): 49–53.
31. Руководство по иммуногистохимической диагностике опухолей человека /Под ред. СВ Петрова и НТ Райхлина. Казань, 2004. 456 с.
32. Упоров АВ, Семиглазов ВФ, Пожарисский КМ. Иммуногистохимическое изучение клеток рака молочной железы с использованием различных маркеров пролиферации. Арх. Пат. 2000; 2: 26–30.
33. Pietilainen T, Lipponen P, Aalotomaa S et al. The important prognostic value of Ki-67 expression as determined by image in breast cancer. J. Cancer Res. Clin. Oncol 1996: 122: 687–692.
34. Ohtani M, Isozaki H, Fujii K et al. Impact of the expression of cyclin-dependent kinase inhibitor p27Kip1 and apoptosis in tumor cells on the overall survival of patients with non-early stage gastric carcinoma. Cancer 1999; 85: 1711–1718.
35. Tan P, Cady B, Wanner M et al. The cell cycle inhibitor p27 is an independent prognostic marker in small (T1a,b) invasive breast carcinoma. Cancer Res. 1997; vol. 57: 1259–1263.
36. Paul J van Diest, Johannes S de Jong, Jan PA Baak, Rob JAM Michalides, Elsker van der Wall. Prognostic value of proliferation and apoptosis in breast cancer//Prognostic and predictive factor in breast cancer/Eds: Walker RA London: Martin Duitz, 2003: 57–85.
37. Folkman J. Tumor angiogenesis//The molecular Basis of Cancer/Eds: J Mendelsohn, PM Howley, MA Israel, Liotta. Philadelphia: Saunders, 1995: 206–232.
38. Nagy JA, Brown LF, Senger DR, Lanir N, Van de Water L, Dvorak AM, Dvorak HF. Pathogenesis of tumor stroma generation: a critical role for leaky blood vessels and fibrin deposition. Biochim. Biophys. Aсta. 1989; 948: 305–326.
39. Zetter BR. Angiogenesis and tumor metastasis. Annu Rev Med 1998; 49: 409–424.
41. Nguyen M, Watanabe H, Budson AE et al. Elevated levels of an angiogenic peptide, basis fibroblast growth factor, in the urine of patients with a wide spectrum of cancers. J Natl Cancer Inst 1994; 86: 356–361.
42. Фильченков АА. Молекулярные механизмы метастазирования опухолей. Онкология. 1999; 2: 122–135.
43. Isner JM, Asahara T. Therapeutic angiogenesis. Front Biosci 1998; 3: 46–69.
44. Folkman J.Tumor angiogenesis:therapeutic implications. N Engl J Med 1971; 286: 1182–1186.
45. Hanahan D, Weinberg RA. The hallmarks of cancer. Cell 2000: 100; 67–70.
46. Brown LF, Detmar M, Claffey K et al. Vascular permeability factor/vascular endothelial growth factor: a multifunctional angiogenic cytokine. EXS 1997; 79: 233–269.
47. Reinmuth N, Parikh AA, Ahmad SA еt al. Biology of angiogenesis in tumors of the gastrointestinal tract. Microso Res Tach 2003; 60: 199–207.
48. Berns EM, Klijn JG, Look MP et al. Combined vascular endothelial growth factor and TP53 status predicts pool response to tamoxifen therapy in estrogen receptor-positive advanced breast cancer. Clin Cacer Res 2003; 9: 1263–1268.
49. Manders P, Beex LV, Tjan-Heijnen VC et al. The prognostic value of vascular endothelial growth factor in 674 node-negative breast cancer patients who did not receive adjuvant systemic therapy. Br J Cancer 2002; 87: 772–778.
50. Brown LE, Dermar M, Claffey K et al. Vascular permeability factor/vascular endothelial growth factor: a multifunctional angiogenic cytokine. EXS 1997; 79: 233–269.
51. Ferrara N. Volecular and biological properties of vascular endothelial growth factor. J Mol Mad 1999; 77: 527–543.
52. Ferrara N. Vascular endothelial growth factor and the regulation of angiogenesis. Recent Prog Horm Res 2000; 55: 15–36.
53. Brown LF, Veo KT, Berse B et al. Expression of vascular permeability factor (vascular endothelial growth factor) by epidermal keratinocytes during wound healing. J Exp Med 1992; 176: 1375–1379.
54. Ferrara N, Gerber HP, LeCouter J. The biology of VEGF an its receptors. Nat Med 2003; 9: 669–676.
55. Ogaws S, Oku A, Sawano A et al. A novel type of vascular endothelial growth factor,VEGF-E, (NZ7 VEG), preferentially utilizes KDR/Fik-1 receptor and carries a potent mitotic actvit without heparin-biding domain. J Biol Chem 1998; 273: 31273–31282.
56. Terman B. Identification of a new endothelial cell growth factor receptor tyrosine kinase. Oncogene 1991; 6: 1677–1683.
57. Pfsvonen K, Puolakkainen P, Jussils L et al. Vascular endothelial growth factor receptor-3 in lymphangiogenesis in wound haling. Am J Pathol 2000; 156: 1499–1504.
58. Dvorak HF. Vascular permeability factor /vascular endothelial growth factor: A critical cytokine in tumor angiogenesis an a potential target for diagnosis and therapy. J Clin Oncol 2002; 20: 4368–4380.
59. Brem S, Cotran R, Folkman J. Tumor angiogenesis: a quantitative method for histologic grading. J Natl Cancer Inst 1972; 48: 347–56.
60. Weidner N, Semple JP, Welch WR, Folcman J. Tumor angiogenesis and metastasis — correlation in invasive breast carcinoma. N Enl J Med 1991; 324: 1–8.
61. Tavassoly FA, Norris HJ. A comparison of the results of long-term follow-up for atypical intraductal hyperplasia and intraductal hyperplasia of the breast. Cancer 1990; 65: 518–529.
62. Dupont WO, Page DL. Risk factors for breast cancer in women with proglifrative breast disease. N Engl J Med 1985; 321:146–51.
63. Fidier IJ, Gersten MD, Hart IR. The biology of cancer invasion and metastasis. Adv Cancer Res 1978; 28: 149–250.
64. Nicolson G. Cancer metastasis. Sci Am 1979; 240: 66–76.
65. liotta L, Saidel G, Kleinerman J. The significance of hematogenous tumor cell clumps in the metastatic process. Cancer Res 1976; 36: 889–894.
66. Bodian CA, Perzin KH, Lattes R, Hoffman P. Abernathy. Prognostic significance of beningn proliferative breast disease. Cancer 1993; 71: 3896–3907.
67. Dupont WD, Page DL. Breast cancer risk associated with proliferative disease, age at first birth, and a family history of breast cancer. Am J Epidmiol 1987; 125: 769–779.
68. Barth RJ, Danforth DN, Venson DJ, Straus KL, Teresa d’Angelo, Marino MJ, Gerber L. Level of axillary involvement o lymph node metastases from breast cancer is not an independent predictor of survival. Arch Surg 1991; 126: 574–577.
69. Osborne CK. Prognostic factors in breast cancer. Priciples Pract Oncol 1990; 4: 1–11.
70. Rosen PP, Groshen S. Factors influencing survival and prognosis in early breast carcinoma (T1N0M0–T1N1M0). Assessment of 644 patients with median follow-up of 18 years. Surg Clin North Am 1990; 70: 937–962.
71. Trojani M, de Mascarell, Bonichon F, Coindre JM, Delsol G. Micrometastases to axillary lymph nodes from carcinoma of breast: detection by immunohistochemistry and prognostic significance. Br J Cancer1987; 55: 303–306.
72. Nasser IA, Lee AK, Bossari S, Saganich R, Heatley G, Silverman Ml. Occult axilary lymph node metastases in «nod — negative» breast carcinoma. Hum Pathol 193; 24: 950–957.
73. Scarff TW, Handley RS. Prognosis in carcinoma of the breast. Lancet 1938; 1: 582–583.
74. Srivastova A, Laidler P, Hughes LE, Woodcock J, Shedden EJ. Neovascularization in human cutaneous melanoma: a quantitative morphlogical and Doppler ultrasound stady. Eur J Cancer Clin Oncol 1986; 22: 1205–1209.
75. Srivastova A, Laidler P, Davies R, Hughes K, Hughes LE. The prognostic significance of tumor vascularity in intermediate-thickness (0,76-4,0 mm thick) skin melanoma. Am J Pathol 1988; 133: 419–23.
76. Kohno Y, Iwanari O, Kitao M. Prognostic importance of histologic vascular density in cervical cancer treated with hypertensive intraarterial chemotherapy. Cancer 1993; 72: 2394–2400.
77. Zatterstrom UK, Brun E, Willen R, Kjellen E, Wennerberg J. Tumor angiogenesis and prognosis in squamous cell carcinoma of the head and neck. Head & Neck 1995; 17: 312–318.
78. Brawer MK, Deering RE, Brown M, Preston SD, Bigler SA. Predictors of pathologic stage in prostate carcinoma. Cancer 1994; 73: 678–687.
79. Leedy DA, Trune DR, Kronz JD, Weidner N, Cohen JI. Tumor angiogenesis, the p53 antigen and cervical metastasis in squamous carcinoma. Otolaryngol Head Neck Surg 1994; 111: 417–422.
80. Kainz C, Speises P, Wanner C, Obermair A, Temrfer C, Sliutz G, Reinthaller A, Breitenecker G. Prognostic value of tumor microvessel density in cancer of the uterine cervix stage IB to IIB. Anticancer Res 1995; 15: 1549–1551.
81. Fox SB, Leek AK, De Lellis RA. Tumor angiogenesis in node-negative breast carcinomas: relationship with epidermal growth factor, estrogen receptor and survival. Breast Can Res Treat 1994; 29: 109–116.
82. Fox SB, Leek RD, Weeks RM, Gatterm KC, Harris AL. Quantitation and prognostic value of breast cancer angiogenesis: comparison of microvessel density, Chalkley count and computer image analysis. J Pathol 1995; 177: 275–283.
83. Gasparini G, Barbareschi M, Boracchi P, Bevilacqua P, Verderio P, Dalla Parma P, Menard S. 67-kDa laminin-receptor expression adds prognostic information to intra-tumoral microvessel density in node-negative breast cancer. Int J Cancer 1995; 60: 7604-7610.
84. Cabanas RM. An approach for the treatment of penile carcinoma. Cancer 1977; 39: 456–466.
85. Uren RF, Hjwman-Giles RB, Thompson JF, Malouf D, Ramsey-Stewart G, Niesche FW, Renwick SB. Mammary lymphoscintigraphy in breast cancer. J Nucl Med 19995; 36: 1775–1780.
86. Krag D, Weaver D, Ashikaga T, Moffatt F, Klimberg VS, Shriver C, Feldman S, Kusminsky R, Gadd M, Kuhn J, Hsrlow S, Beitsch P. The sentinel node in breast cancer-a multicenter validation study. N Engl J Med 1998; 339: 941–946.
87. Smith RAF, Krag DN, Weaver DL. Decreased histologic accuracyof detecting axillary node metastases may follow submission of nodal tissue for ancillary studies. Mod Pathol 1998; 11: 28A
88. Jannink I, Fan M, Nagy S, Rayudu G, Dowlatshahi K. Serial sectioning of nodes in patients with breast cancer: a pilot study. Ann Surg Oncol 1998; 5: 310–314.
89. Guenther JM, Krishnamoorthy M, Tan LR. Sentinel lymphadenectomy for breast cancer in a community managed care setting. Cancer J Sci Am 1997; 3: 336– 340.
90. McGuire WL, Clark GM. Prognostic factors and treatment decisions in axillary node-negative breast cancer. NEJM1992;326:1756-1761
91. Veronese SM, Barbareschi M, Morelli L, Aldovini D, Mauri FA, Caffo O, Gambacorta M, Palma PD. Predictive value of ERID5 antibody immunostaining in breast cancer. A paraffin-based retrospective study of 257 cases. Appl immunohistochem 1995; 3: 85–90.
92. Courdi A, Hery M, Dahan E, Gioanni J, Abbes M, Monticelli J, Ettore F, Mol JL, Namer M. Factors affecting relapse in node-negative breast cancer. A multivariate analysis including labeling index. Eur J Clin Oncol 1989; 25: 351–356.
93. Butler JL, Bretsky S, Mendex-Botet C, Kinne DW. Estrogen receptor protein of breast cancer as a predictor of recurrence. Cancer 1985; 55: 1178–1181.
94. Mohammed RH, Lakatua DJ, Haus E, Yasmineh WJ. Estrogen and progesterone receptors in human cancer: correlation with histologic subtype abd degree of differention. Cancer 1986; 58: 1076–1081.
95. McCarty KS Jr, Barton TK, Fetter BF, Woodard BH, Mossler JA, Reeves W, Daly J, Wilkinson WE, McCarty KS Sr. Correlation of estrogen and progesterone receptors with histologic differentiationin mammary carcinoma. Cancer 1980; 46: 2851–2858.
96. Osborne CK, Yochmowitz MG, Knight III WA, McGuire WL. The value of estrogen and progesterone receptors in the treatment of the breast cancer. Cancer 1980; 46: 2884–2888.
97. Battifora H, Mehta P, Ahn C, Esteban JM. ER immunohistochemistry assay in paraffin-embedded tissue. A better gold standart? App Immunohistochemistry 1993; 1:39–45.
98. Andersen J et al. The prognostic value of immunohistochemical ER analisis in paraffin-embedded and frozen sections versus that of steroid-binding assays. Eur J Cancer 1990; 26: 442–449
99. Pertschuk LP, Eisenberg KB, Carter AC, Feldman JG. Immunohistologic localisazation of estrogen receptors in breast cancer with monoclonal antibodies. Correlation with biochimistry and clinical endocrine response. Cancer 1985; 55: 1513–1518.
100. Jonat W, Maass HM, Stegner HE. Immunohistochemical measurement of estrogen receptors in breast cancer tissue. Cancer Res (Suppl.) 1986; 46: 4296s.
101. Pertschuk LP, Kim DS, Nayer K, Feldman JG, Eisenberg KB, Carter AC, Rong ZT, Thelmo WL, Fleisher J, Greene GL. Immunohistochemical estrogen and progesterone receptors assays in breast cancer with monoclonal antibodies. Cancer 1990; 66: 1663–1670.
102. de Mascarel I, Soubeyran I, MacGrogan G, Wafflart J, Bonichon F, Durand M, Avril A, Mauriac L, Trojani M, Coindre JM. Immunohistochemical analisis of estrogen receptors in 938 breast carcinomas. Concordance with biochimical assay and prognostic sighificance. Appl Immunohistochem 1995; 3: 222–231.
106. Wilbur DC, Willis J, Mooney RA, Fallon MA, Moynes R, di sant’Agnese PA. Estrogen and progesterone receptors detection in archival formalin-fixed, paraffin-embedded tissue from breast carcinomas: A comparison of immunohistochemical with the dextran-coated charcol assay. Mod Pathol 1992; 5: 79–84.
107. Key TJ, Pike MC.The role of oestrogens and progestegens in the epidemiology and prevention of breast cancer. Eur J Cancer Clin Oncol 1988; 24: 29–43.
108. Bernstein L, Ross RK. Endogenous hormones and breast cancer risk. Epidemiol Rev 1993; 15: 48–65.
109. Key TJ. Serum oestradiol and breast cancer risk 1999; 6: 175–180.
110. Davis S, Mirick DK, Stevens RG. Night shift work, light at night, and risk of breast cancer. J Natl Cancer inst 2001; 93: 1557–1562.
111. Schernhammer ES, Laden F, Speizr FE, Willett WC, Hunter DJ, Kawachi I, Colditz GA. Rotating night shifts and risk of breast cancer in women participating in the nurses’ health study. J Natl Cancer Inst 2001; 93: 1563–1568.
112. Winkler B, Alvarez S, Richart RM, Crum CP. Pitfalls in the diagnosis of endometrial neoplasia. Obstet gynecol 1984; 64: 185–194.
113. International Agency for Research on Cancer. IARC Handbooks of Cancer Prevention. Weight Control and Physical Activity 2002;Vol. 6: IARC Press: Lyon.
114. Smith-Warner SA, Spiegelman D, Yaun SS, vander Brandt PA, Folsom AR, Goldbohm RA, Graham S, Holmberg L, Howe GR, Marshll JR, Miller AB, Potter JD, Speizer FE, Willett WC, Wolk A, Hunter DJ. Alcohol and breast cancer in women: a pooled analysis of cohort studies. JAMA 1998; 279: 535–540.
115. Longnecker MP. Alcoholic beverage consumption in relation to risk of beast cancer: meta-analysis an review. CancerCauses Control 1994; 5: 73–82.
116. End C, Parsons R. Cowden syndrome. In: The Genetic Basis of Human Cance.B Vogelstein, K Kinzler (Eds) 1998; New Vork: MgGraw-Hil: 519–526.
.116а Emoto M, Iwasaki H, Kawarabayashi T, Egami D, Voshitake H, Kikuchi M, Shirakawa K. Primary osteosarcoma of the uterus: report of a case with immunohistochemical analysis. Gynecol Oncol 1994; 54: 385–388.
117. Albano W. Recabaren J. Lynch H. Natural history of hereditary cancer of the breast and colon. Cancer 1982; 50: 360–363.
118. Любченко Л.Н. Гарькавцева Р.Ф. Клинико-генетическая гетерогенность семейного рака молочной железы. Современная онкология 2004; 6: 1–6.
119. Gorski B, Debniak T, Masoje B. Gremlin 657de15 mutation in the NBSI gene in breast cancer patients. BCLC Familial Cancer 2003; 2: 214–215.
120. Liaw D, Marsh D, Li J. Germline mutations of the PTEN gene in Cowden disease, an inherited breast and thyroid cancer syndrome. Nat Genet 1997; 16: 64.
121. Ford D, Easton D, Stratton M. Genetic heterogeneity and penetrance analysis of the BRCA1 and BRCA2 genes in breast cancer families. Am J Hum Genet 1998; 62: 676–689.
122. Abeliovich D, Kaduri L, Lerer I. The founder mutations 185 del AG and 5382 insCin BRCA1 and 26174 deLT in BRCA2 appear in 60% of ovarian cancer and 30% of early-onset breast cancer patients among Ashkenazi women. Am J Hum Genet 1997; 60: 505.
203. Haagensen CD, Lan N, Lattes R, Bodian C. Lobular neoplasia (so-called lobular carcinoma in situ) of the breast. Cancer 1978; 42: 737–769.
204. Rosen PP, Ernsberger D. Mammary fibromatosis. A benign spindle-cell tumor with significant risk for local recurrence. Cancer 1989; 63: 1363–1369.
203. Elston CW. Ellis IO. Classification of malignant breast disease. In: The Breast Systemic Pathology. CW Elston and IO Ellis (Eds.) 3rd ed. Churchill Livingstone 1998: Edinburgh,p. 239–247.
204. Lakhani SR, Jacquemier J, Sloane JP, Gusterson BA, Anderson TJ, Van de Vijver MJ, Farid LM, Venter D, Antoniou A et al. Multifactorial analysis of differences between sporadic breast cancers and cancers involving BRCA1 and BRCA2 mutations. J Natl Cancer Inst 1998; 90: 1138–1145.
205. Захарцева Л, Тащієв Р, Олійниченко Г, Петрухін В, Нейман А. Методи дослідження рецепторів естрогену і прогестерону в раках молочної залози. Ліки України 2004; 35: 26–28.
206. Bonnier P, Romain S, Giacalone PL, Laffargue F, Martin MP, Piane L. Clinical an biologic prognostic factors in breast cancer diagnosed during post-menopausal hormone replacement therapy. Obstet Gynecol 1995; 85: 11–17.
207. Li CL, Weiss NS, Stanford JL, Daling JR. Hormone replacement therapy in relation to risk of lobular and ductal breast carcinoma in middle-aged women. Cancer 2000; 88: 2570–2577.
208. DeCostranzo D, Rosen PP, Gareen I, Franklin S, Lesser M. Prognosis in infiltrating lobular carcinoma. An analysis of «classical» and variant tumors. Am J Surg Phatol 1990; 14: 12–23.
209. Олійниченко ГП, Захарцева ЛМ, Дроздов ВМ, Нейман АМ, Катеринич АА, Петрухин ВИ. Клиническое значение рецепторов эстрогена, прогестерона и онкобелка Her-2/neu в клетках рака молочной железы. Онкология (Oncology) 2002; 4–1: 33–36.
210. Захарцева ЛМ, Лобанова ОЕ, Григорук АВ, Чешук ВЕ, Щепотин ИБ. Дифференциальная диагностика злокачественных опухолей молочной железы, содержащих остеокласты. Онкология (Oncology) 2004; 6–4: 262–264.
211. Berx G, Cleton-Jansen AM, Nollet F, de Leeuw WJ,van de Vijvet M, Cornelisse C, van Roy F. E-cadherin is a tumor/invasion suppressor gene mutated in lobular breast cancer. EMBO J 1995; 14: 6107–6115.
212. Gaffey MJ, Mills SE, Frierson HF, Zarbo RJ, Boyd LC, Simpson JF, Weiss LM. Medullary carcinoma of the breast: interobserver variability in histopathologic diagnosis. Mod Pathol 1995; 8: 31–38.
213. Pedersen L, Lasen JK, Christensen IJ, Lykkesfeldt A, Holck S, Schiodt T. DNA loidy and S-phase fraction in medullary carcinoma of the breast – a flow cytometric analysis using archival material. Breast Cancer Res Treat 1994; 29: 297–306.
214. Jensen ML, Kiaer H, Andersen J, Jensen V, Melsen F. Prognostic comparison of three classifications for medullary carcinomas of the breast. Histopathology 1997; 30: 523–532.
215. Ridolfi RL, Rosen PP, Port A, Kinne D, Mike V. Medullary carcinoma of the breast: a clinicopathologic study with 10 year follow-up. Cancer 1977; 40: 1365–1385.
216. Kajiwara M, Toyoshima S, Yao T, Tanaka M, Tsuneyoshi M. Apotosis and ocell proliferation in medullary carcinoma of the breast: a comparative study between medullary and non-medullary carcinoma using the TUNEL method and immunohistochemistry. J Surg Oncol 1999; 70: 209–216.
217. Kotlan B, Gruel N, Zafrani B, Furedi G, Foldi J, Petranyi G, Fridman W, Teilaud J. Immunoglobulin variable regions usage by B-lymphocytes infiltrating a human breast medullary carcinoma. Immonology Letters 1999; 65: 43–151.
218. Eisinger F, Jacquemier J, Charpin C, Stoppa-Lyonnet D, Bressac-de Paillerets B, Peyrat JP, Longy M, Giunebretiere JM, Sauvan R, Nogushi T, Birnbaum D, Sobol H. Mutation at BRCA1: the medullary breast carcinoma revisited. Cancer Res 1998; 58: 1588–1592.
219. de Cremoux P, Salomon AV, Liva S, Dendale R, Bouchind’homme B, Martin E, Sastre-Garau X, Magdelenat H, Fourquet A, Soussi T. p53 mutation as a genetic trait of typical medullary breast carcinoma. J Natl Cancer Inst 1999; 91: 641–643.
220. Jensen ML, Kiaer H, Anderson J, Jensen V, Melsen F. Prognostic comparison of three classification for medullary carcinoma of the breast. Histopatology 1997; 30: 523–532.
221. Azzopardi JG, Eusebi V. Melanocyte colonization and pigmentation of breast carcinoma. Histopatology 1977; 1: 21–30.
222. Towfighi J, Simmonds MA, Davidson EA. Mucin and fat emboli in mucinous carcinomas. Cause of hemorrhagic cerebral infarcts. Arch Pathol Lab Med 1983; 170: 646–649.
223. Koenin C, Tavassoli FA. Mucinous cystadenocarcinoma of the breast. Am J Surg Pathol 2000; 8: 303–315.
224. Fisher ER, Palecar AS, Redmond C, Barton B, Fisher B. Pathologic finding from the National Surgical Adjuvant Breast Project (protocol no. 4). VI. Invasive papillary cancer. Am J Surg Pathol 1980; 73: 313–322.
225. Fisher ER, Anderson S, Redmond C, Fisher B. Pathologic finding from the National Surgical Adjuvant Breast Project protocol B-06. 10-year pathologic and clinical prognostic discriminants. Cancer 1993; 71: 2507–2514.
226. Mazoujian G, Pincus GS, Davis S, Haagensen DE Je. Immunohistochemistry of a gross cystic disease fluid protein (GCDFP-15) of the breast. A marcer of apocrine epithelium and breast carcinomas with apocrine features. Am J Surg Pathol 1997; 110; 105–112.
227. Iacocca MV, Maia DM. Bilateral infiltrating lobular carcinoma of the Breast with osteoclast-like giant cells. Breast J. 2001;7; 60–65.
228. Ng WK. Fine needle aspiration cytology of invasive cribriform carcinoma of the breast with osteoclastic giant cells: a case report. Acta Cytol.2001;45; 593–598.
229. Tavassoli FA. Carcinoma with osteoclastic giant cells. Pathology of the breast, Appleton and Lange: 1992, Norwalk, Connecticut.
230. Wargotz ES, Norris HJ. Metaplastic carcinoma of the Breast: V. Metaplastic carcinoma with osteoclastic giant cells. Hum Pathol 1990; 21: 1142–1150.
231. Tumors of the Breast and Female genital organs (Pathology and Genetics). World Health Organization Classification of Tumors, Lyon, 2003, 432.
233. Летягин В.И. Органосохраняющие методы лечения больных первичным раком молочной железы (состояние и перспективы развития). Матер VIII Российского онкологического конгресса. М; издат. группа РОНЦ им. Н. Блохина РАМН. 2004: 16–22.